个性化文献订阅>期刊> Bioorganic & Medicinal Chemistry Letters
 

1,5-Benzodiazepine inhibitors of HCV NS5B polymerase

  作者 McGowan, D; Nyanguile, O; Cummings, MD; Vendeville, S; Vandyck, K; Van den Broeck, W; Boutton, CW; De Bondt, H; Quirynen, L; Amssoms, K; Bonfanti, JF; Last, S; Rombauts, K; Tahri, A; Hu, LL; Delouvroy, F; Vermeiren, K; Vandercruyssen, G; Van der Helm, L; Cleiren, E; Mostmans, W; Lory, P; Pille, G; Van Emelen, K; Fanning, G; Pauwels, F; Lin, TI; Simmen, K; Raboisson, P  
  选自 期刊  Bioorganic & Medicinal Chemistry Letters;  卷期  2009年19-9;  页码  2492-2496  
  关联知识点  
 

[摘要]Optimization through parallel synthesis of a novel series of hepatitis C virus (HCV) NS5B polymerase inhibitors led to the identification of (R)-11-(4-benzyloxy-2-fluorophenyl)-6-hydroxy-3,3-dimethyl-10-(6-methylpyridine-2-carbonyl)-2,3,4,5,10,11-hexahydro-dibenzo[b,e][1,4]diazepin-1-one 11zc and (R)-11-(4-benzyloxy-2-fluorophenyl)-6-hydroxy-3,3-dimethyl-10-(2,5-dimethyloxazol-4-carbonyl)2,3,4,5,10,11-hexahydro-dibenzo[b,e][1,4]diazepin-1-one 11zk as potent ( replicon EC50 = 400 nM and 270 nM, respectively) and selective (CC50 > 20 mu M) inhibitors of HCV replication. These data warrant further lead-optimization efforts. (c) 2009 Elsevier Ltd. All rights reserved.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内